Axitinib/axitinib manufacturers and supply status

Axitinib is a highly selective angiogenesis inhibitor that belongs to the multi-target tyrosine kinase inhibitor (TKI) class of drugs. It mainly blocks tumor neovascularization by inhibiting the vascular endothelial growth factor receptor (VEGFR) signaling pathway, thereby inhibiting tumor growth and metastasis. It has been approved for marketing in many countries around the world and is mainly suitable for second-line and first-line treatment of advanced renal cell carcinoma (RCC). It especially shows high clinical value in immune combination therapy strategies.

The original drug of axitinib is developed and produced by Pfizer Inc. (Pfizer Inc.) and complies with international Good Manufacturing Practice (GMP) standards. The produced axitinib is supplied to multiple markets around the world, including North America, Europe, Asia and other regions. With a mature production system and strict quality control, the quality stability and traceability of original axitinib have been widely recognized globally.

In terms of supply, the original axitinib is currently on the market in mainland China, the United States, the European Union, Japan, Australia and other countries and regions. The supply in the domestic market mainly relies on Pfizer China's import and distribution channels, and is sold through regular hospital pharmacies and authorized pharmacies approved by the National Medical Products Administration (NMPA). At the same time, some cross-border drug purchasing platforms and overseas pharmacies can also provide the supply of original drugs, but they must comply with local pharmaceutical regulations and prescription requirements.

In recent years, with the advancement of patent protection period, the production of generic drugs of axitinib has appeared in some countries and regions. Many pharmaceutical companies in India, Laos and other places have started producing generic axitinib drugs and supply them to their own countries and some overseas markets. Although generic drugs have obvious advantages in price, manufacturer qualifications, quality control standards, and drug stability are factors that patients and doctors need to consider.

Reference materials:https://en.wikipedia.org/wiki/Axitinib